The Schall Law Firm Announces Class Action Lawsuit Against Geron Corporation
Los Angeles, CA – April 3, 2025
The Schall Law Firm, a leading national securities firm, announces the filing of a class action lawsuit against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. This class action lawsuit involves investors who purchased Geron securities between June 7, 2024, and February 25, 2025, inclusive (the “Class Period”).
Allegations of Securities Law Violations
According to the complaint, Geron made false and misleading statements to the market during the Class Period. Specifically, the Company misrepresented the progress and prospects of its Imetelstat development program. The truth was revealed on February 25, 2025, when Geron announced that the Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for Imetelstat, citing insufficient data to support approval.
Impact on Geron Shareholders
Following this news, Geron’s stock price dropped significantly, causing substantial losses to investors. The Schall Law Firm is committed to recovering losses for affected investors and encourages investors who purchased Geron securities during the Class Period to contact the firm before May 12, 2025.
Global Implications
The implications of this lawsuit extend beyond Geron shareholders. The FDA’s decision to reject the NDA for Imetelstat highlights the importance of transparency and accuracy in clinical trial reporting. This incident underscores the need for stricter regulations and oversight in the biotech industry to protect investors and ensure the development of safe and effective treatments.
- Transparency and accuracy in clinical trial reporting are crucial for investor protection.
- The biotech industry requires stricter regulations and oversight to ensure the development of safe and effective treatments.
Conclusion
The Schall Law Firm’s class action lawsuit against Geron Corporation serves as a reminder of the importance of transparency and accuracy in the biotech industry. As this case unfolds, it will be essential for investors to remain informed and vigilant. Should you have any questions or concerns regarding this lawsuit, please contact The Schall Law Firm.
About The Schall Law Firm
The Schall Law Firm is a national shareholder rights litigation firm that represents investors all over the world. With offices in Los Angeles, San Diego, and New York, the firm has been a leader in securities class action lawsuits since its inception.
